THE US Food and Drug Administration has announced the approval of Valeant Pharmaceuticals' Siliq (brodalumab) injection for the treatment of adults with moderate-to-severe plaque psoriasis.
Brodalumab binds to a protein that causes inflammation, inhibiting the inflammatory response that plays a role in the development of the condition.
Under the authorisation, patients must sign a Patient-Prescriber Agreement Form because of an observed risk of suicidal ideation and behaviour associated with the medication.
In addition, pharmacies must be certified with the program and must only dispense to patients who are authorised to receive Siliq.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Feb 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Feb 17
